The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, when a record fine is looming over a company, it can also be dependent on the court rooms.
Gilead will be breathing a sigh of relief, after a judge overturned a record $2.54 billion decision against it. The case was brought by MSD, known as Merck in North America, regarding Gilead’s blockbuster hepatitis C drugs, Sovaldi and Harvoni.
MSD had alleged that Gilead infringed its patents and had initially won the case in December of 2016.
